Kura Oncology Stock Today
| KURA Stock | USD 18.75 0.02 0.11% |
Performance1 of 100
| Odds Of DistressLess than 9
|
Kura Oncology is trading at 18.75 as of the 25th of April 2024, a 0.11% increase since the beginning of the trading day. The stock's open price was 18.73. Kura Oncology has less than a 9 % chance of experiencing financial distress in the next few years but had a somewhat weak performance during the last 90 days. Equity ratings for Kura Oncology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of March 2024 and ending today, the 25th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 22nd of September 2015 | Category Healthcare | Classification Health Care |
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California. Kura Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 76.18 M outstanding shares of which 10.41 M shares are now shorted by private and institutional investors with about 9.57 trading days to cover. More on Kura Oncology
Follow Valuation Options Odds of Bankruptcy
Financial Report 8th of May 2024
Kura Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Kura Oncology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Kura Oncology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman | Troy Wilson | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Biotechnology, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Kura Oncology report their recommendations after researching Kura Oncology's financial statements, talking to executives and customers, or listening in on Kura Oncology's conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Kura Oncology. The Kura consensus assessment is calculated by taking the average forecast from all of the analysts covering Kura Oncology. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key measurements obtained from Kura Oncology's financial statements, Kura Oncology is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Kura Oncology is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Kura Oncology's financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Kura Oncology's success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Kura Oncology's financial leverage. It provides some insight into what part of Kura Oncology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Kura Oncology (KURA) is traded on NASDAQ Exchange in USA. It is located in 12730 High Bluff Drive, San Diego, CA, United States, 92130 and employs 142 people. Kura Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.41 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Kura Oncology's market, we take the total number of its shares issued and multiply it by Kura Oncology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Kura Oncology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 76.18 M outstanding shares of which 10.41 M shares are now shorted by private and institutional investors with about 9.57 trading days to cover.
Kura Oncology currently holds about 450.26 M in cash with (124.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.73.
Check Kura Oncology Probability Of Bankruptcy
Ownership AllocationKura Oncology holds a total of 76.18 Million outstanding shares. The majority of Kura Oncology outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Kura Oncology to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Kura Oncology. Please pay attention to any change in the institutional holdings of Kura Oncology as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Kura Ownership Details
Kura Stock Price Odds Analysis
What are Kura Oncology's target price odds to finish over the current price? Depending on a normal probability distribution, the odds of Kura Oncology jumping above the current price in 90 days from now is about 78.75%. The Kura Oncology probability density function shows the probability of Kura Oncology stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.761. This indicates as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Kura Oncology will likely underperform. Additionally, kura Oncology has an alpha of 0.3872, implying that it can generate a 0.39 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
Based on a normal probability distribution, the odds of Kura Oncology to move above the current price in 90 days from now is about 78.75 (This Kura Oncology probability density function shows the probability of Kura Stock to fall within a particular range of prices over 90 days) .
Kura Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Kura Oncology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Kura Oncology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kura Oncology's value.| Instituion | Recorded On | Shares | |
| Foresite Capital Management Iv, Llc | 2023-12-31 | 1.8 M | |
| Artal Group S A | 2023-12-31 | 1.8 M | |
| Sofinnova Ventures | 2023-12-31 | 1.7 M | |
| Geode Capital Management, Llc | 2023-12-31 | 1.7 M | |
| Citadel Advisors Llc | 2023-09-30 | 1.5 M | |
| Tcg Crossover Management, Llc | 2023-12-31 | 1.4 M | |
| Franklin Resources Inc | 2023-12-31 | 1.4 M | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.3 M | |
| Paradigm Biocapital Advisors Lp | 2023-12-31 | 1.3 M | |
| Blackrock Inc | 2023-12-31 | 7.3 M | |
| Suvretta Capital Management, Llc | 2023-12-31 | 6.9 M |
Kura Oncology Historical Income Statement
Kura Oncology Income Statement is one of the three primary financial statements used for reporting Kura's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Kura Oncology revenue and expense. Kura Oncology Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Kura Oncology's Other Operating Expenses is projected to increase significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 173.2 M, whereas Operating Income is projected to grow to (157.5 M). View More FundamentalsKura Stock Against Markets
Picking the right benchmark for Kura Oncology stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Kura Oncology stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Kura Oncology is critical whether you are bullish or bearish towards Kura Oncology at a given time. Please also check how Kura Oncology's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Kura Oncology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Kura Oncology Corporate Directors
Kura Oncology corporate directors refer to members of a Kura Oncology board of directors. The board of directors generally takes responsibility for the Kura Oncology's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Kura Oncology's board members must vote for the resolution. The Kura Oncology board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Steven Stein | Director | Profile | |
| Thomas Malley | Director | Profile | |
| Mary Szela | Director | Profile | |
| Faheem Hasnain | Independent Director | Profile |
How to buy Kura Stock?
Before investing in Kura Oncology, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Kura Oncology. To buy Kura Oncology stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Kura Oncology. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Kura Oncology stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Kura Oncology stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Kura Oncology stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Kura Oncology, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Kura Stock please use our How to Invest in Kura Oncology guide.
Already Invested in Kura Oncology?
The danger of trading Kura Oncology is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Kura Oncology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Kura Oncology. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Kura Oncology is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Kura Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kura Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kura Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kura Oncology Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kura Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Kura Stock refer to our How to Trade Kura Stock guide.You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities |
Is Kura Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kura Oncology. If investors know Kura will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kura Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Return On Assets (0.23) | Return On Equity (0.37) |
The market value of Kura Oncology is measured differently than its book value, which is the value of Kura that is recorded on the company's balance sheet. Investors also form their own opinion of Kura Oncology's value that differs from its market value or its book value, called intrinsic value, which is Kura Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kura Oncology's market value can be influenced by many factors that don't directly affect Kura Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kura Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kura Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kura Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.